Leading international society embarks on
multi-year initiative to increase clinician awareness of factor
XI/XIa inhibition
BANGKOK, June 21, 2024 /PRNewswire/ -- The International
Society on Thrombosis and Haemostasis (ISTH), the leading worldwide
not-for-profit organization dedicated to advancing the
understanding, prevention, diagnosis, and treatment of conditions
related to thrombosis and hemostasis, announces the official launch
of new education titled "ISTH Emerging Therapies in
Thrombosis—Factor XI/XIa Inhibitors". The organization is embarking
on a comprehensive, globally relevant educational initiative to
increase clinician awareness of factor XI (FXI) inhibition and how
it might lead to the development of safer anticoagulation
therapy.
In early 2023, the ISTH organized the multi-disciplinary,
international Factor XI/XIa Educational Steering Committee, a group
of world-renowned experts led by Jeff
Weitz, MD, to survey a sample of the multi-disciplinary
target audiences for this education.
By utilizing the results of the survey, with input from other
educational sources, the committee designed a dynamic educational
roadmap to guide the development of the factor XI/XIa multi-year
initiative.
The ISTH will develop a centralized and branded learning center
called the "Learning Hub" that will be integrated within the ISTH
Academy, an online platform providing Society members with premier
access to educational resources. It will be launched in conjunction
with an in-person learning experience on-site at the ISTH Academy
booth at the ISTH's 2024 Congress in Bangkok, Thailand, from June 22-26, 2024.
The in-person learning experience will focus on the topic The
Promise of Factor XI/XIa Inhibitors: Anticoagulation Without the
Risk of Bleeding. This 20-minute lecture will be recorded and
broadcast in the ISTH Academy booth throughout the meeting and
shared on the ISTH Academy after the Congress.
"Launching the factor XI/XIa educational roadmap in Bangkok is an exciting opportunity to kick off
this global education initiative," said Weitz, the ISTH's recently
elected Secretary General for 2024-2028 term. "Our leadership in
the steering committee and feedback from the greater thrombosis and
hemostasis community has allowed us to understand the current needs
and create meaningful education in factor XI/XIa inhibition."
The offerings inside the Learning Hub on the ISTH Academy
platform will include:
- The results of the survey and a factor XI/XIa educational
roadmap
- A glossary of terms to aid learners in understanding current
and evolving terminology related to FXI/XIa inhibition
- Educational content developed by the ISTH and links to
external resources
- A research round-up, a collation of current trials and research
for all FXI/XIa inhibitor indications under investigation
- Subscription-style updates, allowing the ISTH to provide
new research and educational activities that will be released
throughout the year
ISTH Emerging Therapies in Thrombosis—Factor XI/XIa Inhibitors
is supported by educational grants from Bayer, Anthos, and
BMS/J&J. For more information, visit this link.
About the International Society on Thrombosis and Haemostasis
(ISTH)
Founded in 1969, the ISTH is the leading worldwide
not-for-profit organization dedicated to advancing the
understanding, prevention, diagnosis, and treatment of conditions
related to thrombosis and hemostasis. ISTH is an international
medical-scientific professional membership organization with more
than 7,500 clinicians, researchers, and educators working together
to improve the lives of patients in more than 110 countries around
the world. Among its highly regarded activities and initiatives are
education and standardization programs, research activities,
meetings and congresses, peer-reviewed publications, expert
committees, and World Thrombosis Day on 13 October. Visit ISTH
online at www.isth.org.
Logo -
https://mma.prnewswire.com/media/454627/4754468/ISTH_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/isth-announces-launch-of-new-global-education-initiative-in-factor-xixia-inhibition-302174734.html